Total Payments
$35,520
2024 Payments
$3,641
Companies
14
Transactions
49
Medicare Patients
1,414
Medicare Billing
$167,920
Payment Breakdown by Category
Other$17,040 (48.0%)
Consulting$13,809 (38.9%)
Food & Beverage$1,512 (4.3%)
Research$1,463 (4.1%)
Travel$1,357 (3.8%)
Education$339.93 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $13,809 | 6 | 38.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,750 | 4 | 27.4% |
| Honoraria | $7,290 | 4 | 20.5% |
| Food and Beverage | $1,512 | 21 | 4.3% |
| Unspecified | $1,463 | 1 | 4.1% |
| Travel and Lodging | $1,357 | 7 | 3.8% |
| Education | $339.93 | 6 | 1.0% |
Payments by Type
General
$34,057
48 transactions
Research
$1,463
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $15,829 | 16 | $0 (2023) |
| Incyte Corporation | $5,862 | 10 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $3,488 | 5 | $0 (2024) |
| Agios Pharmaceuticals, Inc. | $2,800 | 1 | $0 (2020) |
| Rigel Pharmaceuticals, Inc. | $2,647 | 3 | $0 (2023) |
| Amgen Inc. | $2,596 | 2 | $0 (2020) |
| Celgene Corporation | $1,667 | 5 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $150.00 | 1 | $0 (2024) |
| Gilead Sciences, Inc. | $99.90 | 1 | $0 (2018) |
| Seattle Genetics, Inc. | $99.13 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,641 | 4 | E.R. Squibb & Sons, L.L.C. ($3,343) |
| 2023 | $1,606 | 4 | Rigel Pharmaceuticals, Inc. ($1,477) |
| 2022 | $1,333 | 5 | Rigel Pharmaceuticals, Inc. ($1,170) |
| 2021 | $105.09 | 3 | Epizyme, Inc., ($82.95) |
| 2020 | $5,396 | 3 | Agios Pharmaceuticals, Inc. ($2,800) |
| 2019 | $5,862 | 10 | Incyte Corporation ($5,862) |
| 2018 | $5,072 | 5 | Alexion Pharmaceuticals, Inc. ($4,972) |
| 2017 | $12,506 | 15 | Alexion Pharmaceuticals, Inc. ($10,758) |
All Payment Transactions
49 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/28/2024 | Janssen Scientific Affairs, LLC | TALVEY (Biological) | Consulting Fee | Cash or cash equivalent | $150.00 | General |
| Category: Oncology | ||||||
| 07/08/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $3,342.50 | General |
| 06/28/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $123.68 | General |
| 06/28/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $24.74 | General |
| 06/21/2023 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $29.78 | General |
| Category: Neurology | ||||||
| 06/02/2023 | Alexion Pharmaceuticals, Inc. | — | Education | In-kind items and services | $100.00 | General |
| 03/13/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Honoraria | Cash or cash equivalent | $1,370.00 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 03/13/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $106.57 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 12/11/2022 | Daiichi Sankyo Inc. | — | Food and Beverage | In-kind items and services | $71.60 | General |
| 12/10/2022 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $29.06 | General |
| Category: Hematology | ||||||
| 12/10/2022 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $26.05 | General |
| 12/09/2022 | E.R. Squibb & Sons, L.L.C. | SPRYCEL (Drug) | Education | In-kind items and services | $35.84 | General |
| Category: Oncology | ||||||
| 04/12/2022 | Rigel Pharmaceuticals, Inc. | Tavalisse (Drug) | Honoraria | Cash or cash equivalent | $1,170.00 | General |
| Category: Hematology | ||||||
| 10/26/2021 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Education | In-kind items and services | $11.07 | General |
| Category: Hematology | ||||||
| 10/11/2021 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Education | In-kind items and services | $11.07 | General |
| Category: Hematology | ||||||
| 05/14/2021 | Epizyme, Inc., | TAZVERIK (Drug) | Education | In-kind items and services | $82.95 | General |
| Category: ONCOLOGY | ||||||
| 11/25/2020 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $1,947.00 | General |
| 11/25/2020 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $649.00 | General |
| 10/01/2020 | Agios Pharmaceuticals, Inc. | TIBSOVO (Drug) | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| Category: Oncology | ||||||
| 05/14/2019 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $4,920.00 | General |
| 05/03/2019 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $125.00 | General |
| 05/03/2019 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $125.00 | General |
| 05/03/2019 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $46.72 | General |
| 05/03/2019 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $46.72 | General |
| 05/03/2019 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $36.11 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CC-486-DLBCL-001 | Celgene Corporation | $1,463 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 319 | 538 | $154,525 | $40,174 |
| 2022 | 8 | 310 | 582 | $153,777 | $37,655 |
| 2021 | 10 | 405 | 754 | $191,318 | $50,786 |
| 2020 | 10 | 380 | 690 | $155,341 | $39,305 |
Total Patients
1,414
Total Services
2,564
Medicare Billing
$167,920
Procedure Codes
48
All Medicare Procedures & Services
48 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 65 | 161 | $50,071 | $12,317 | 24.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 48 | 83 | $25,793 | $6,448 | 25.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 56 | 72 | $19,160 | $3,509 | 18.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 16 | 40 | $6,876 | $2,544 | 37.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 20 | 24 | $7,848 | $2,510 | 32.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 13 | 21 | $7,945 | $2,416 | 30.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 11 | 20 | $7,572 | $2,301 | 30.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 37 | 42 | $11,200 | $2,227 | 19.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 23 | $5,564 | $2,201 | 39.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 13 | 22 | $3,963 | $1,432 | 36.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 12 | 12 | $4,362 | $1,177 | 27.0% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2023 | 15 | 18 | $4,171 | $1,091 | 26.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 57 | 164 | $49,692 | $12,843 | 25.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 65 | 103 | $27,001 | $5,128 | 19.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 25 | 58 | $17,574 | $4,297 | 24.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 19 | 64 | $10,752 | $3,721 | 34.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 61 | 78 | $20,280 | $3,717 | 18.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 13 | 39 | $9,282 | $3,247 | 35.0% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 22 | 23 | $6,992 | $1,660 | 23.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 14 | 14 | $3,812 | $901.32 | 23.6% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2022 | 11 | 13 | $3,569 | $814.31 | 22.8% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 12 | 15 | $1,845 | $707.60 | 38.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 11 | 11 | $2,978 | $617.29 | 20.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 55 | 153 | $46,308 | $12,017 | 26.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 38 | 126 | $20,723 | $7,424 | 35.8% |
About Dr. John Reagan, MD
Dr. John Reagan, MD is a Hematology & Oncology healthcare provider based in Providence, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/23/2007. The National Provider Identifier (NPI) number assigned to this provider is 1841418944.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Reagan, MD has received a total of $35,520 in payments from pharmaceutical and medical device companies, with $3,641 received in 2024. These payments were reported across 49 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($13,809).
As a Medicare-enrolled provider, Reagan has provided services to 1,414 Medicare beneficiaries, totaling 2,564 services with total Medicare billing of $167,920. Data is available for 4 years (2020–2023), covering 48 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Providence, RI
- Active Since 04/23/2007
- Last Updated 02/13/2017
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1841418944
Products in Payments
- SOLIRIS (Drug) $13,130
- TIBSOVO (Drug) $2,800
- Rezlidhia (Drug) $1,477
- CC-486 (Drug) $1,463
- Tavalisse (Drug) $1,170
- TALVEY (Biological) $150.00
- Biktarvy (Drug) $99.90
- ADCETRIS (Biological) $99.13
- Imbruvica (Drug) $99.00
- OPDIVO (Biological) $87.55
- TAZVERIK (Drug) $82.95
- Pomalyst (Drug) $51.20
- SPRYCEL (Drug) $35.84
- UZEDY (Drug) $29.78
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Providence
Ritesh Rathore, Md, MD
Hematology & Oncology — Payments: $324,296
Hematology & Oncology $324,296
Anthony Mega, Md, MD
Hematology & Oncology — Payments: $193,307
Hematology & Oncology $193,307
Dr. Adam Olszewski, M.d, M.D
Hematology & Oncology — Payments: $47,507
Hematology & Oncology $47,507
Hina Khan, M.d, M.D
Hematology & Oncology — Payments: $19,225
Hematology & Oncology $19,225
Dr. Joseph Dibenedetto, Md, MD
Hematology & Oncology — Payments: $6,205
Hematology & Oncology $6,205
Robert Sokolic, M.d, M.D
Hematology & Oncology — Payments: $5,699
Hematology & Oncology $5,699